Efficacy and Toxicity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms

被引：0
|
作者：
De Divitiis, C. [1 ]
Ottaiano, A. [1 ]
Capozzi, M. [1 ]
Von Arx, C. [2 ]
Faggiano, A. [3 ]
Di Sarno, A. [4 ]
Tatangelo, F. [1 ]
Modica, R. [3 ]
Bianco, A. [4 ]
De Cicco, F. [3 ]
Colao, A. [3 ]
Tafuto, S. [1 ]
机构：
[1] Ist Nazl Tumori Fond G Pascale, Naples, Italy
[2] Imperial Coll, London, England
[3] Univ Naples Federico II, Naples, Italy
[4] AO Colli Monaldi Unit, Naples, Italy
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
neuroendocrine tumors; chemotherapy; temozolomide; metronomic treatment; second-line;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H08
引用
收藏
页码：191 / 191
页数：1
相关论文
共 50 条
  • [1] Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
    Tafuto, Salvatore
    von Arx, Claudia
    Capozzi, Monica
    Tatangelo, Fabiana
    Mura, Manuela
    Modica, Roberta
    Barretta, Maria Luisa
    Di Sarno, Antonella
    Tornesello, Maria Lina
    Colao, Annamaria
    Ottaiano, Alessandro
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)
  • [2] Second-line treatment of advanced neuroendocrine carcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (04): : 304 - 304
  • [3] Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
    De Divitiis, C.
    von Arx, C.
    Grimaldi, A. M.
    Cicala, D.
    Tatangelo, F.
    Arcella, A.
    Romano, G. M.
    Simeone, E.
    Iaffaioli, R. V.
    Ascierto, P. A.
    Tafuto, S.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [4] Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
    C. De Divitiis
    C. von Arx
    A. M. Grimaldi
    D. Cicala
    F. Tatangelo
    A. Arcella
    G. M. Romano
    E. Simeone
    R. V. Iaffaioli
    P. A. Ascierto
    S. Tafuto
    Journal of Translational Medicine, 14
  • [5] Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
    Al-Toubah, T.
    Pelle, E.
    Valone, T.
    Haider, M.
    Strosberg, J.
    PANCREAS, 2021, 50 (03) : 449 - 449
  • [6] Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms
    Al-Toubah, Taymeyah
    Pelle, Eleonora
    Valone, Tiffany
    Haider, Mintallah
    Strosberg, Jonathan R.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (01): : 29 - +
  • [7] Temozolomide-Based Second-Line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours
    Tabaksblat, E.
    Ladekarl, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 72 - 72
  • [8] Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
    Tena, Isabel
    Gupta, Garima
    Tajahuerce, Marcos
    Benavent, Marta
    Cifrian, Manuel
    Falcon, Alejandro
    Fonfria, Maria
    del Olmo, Maribel
    Reboll, Rosa
    Conde, Antonio
    Moreno, Francisca
    Balaguer, Julia
    Canete, Adela
    Palasi, Rosana
    Bello, Pilar
    Marco, Alfredo
    Luis Ponce, Jose
    Francisco Merino, Juan
    Llombart, Antonio
    Sanchez, Alfredo
    Pacak, Karel
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2018, 12
  • [9] A Pilot Phase 2 Study of S-1 and Temozolomide as Second-Line Treatment in Patients With Advanced or Metastatic Neuroendocrine Carcinoma
    Wang, Xin
    Qi, Zhirong
    Tan, Huangying
    PANCREAS, 2020, 49 (03) : 490 - 490
  • [10] Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma
    McGarrah, Patrick W.
    Leventakos, Konstantinos
    Hobday, Timothy J.
    Molina, Julian R.
    Finnes, Heidi D.
    Westin, Gustavo F.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2020, 49 (04) : 529 - 533
12345